Artwork

Content provided by Cambridge Healthtech Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Cambridge Healthtech Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Episode 23: Undruggable No More - Biologists & Engineers Unite to Successfully Deliver Potent RAS-Cleaving Enzyme

21:40
 
Share
 

Manage episode 299414652 series 2967424
Content provided by Cambridge Healthtech Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Cambridge Healthtech Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

There are some proteins that still evade scientists in the race for better therapeutics. Some of the most elusive drug targets in cancer research are RAS oncoproteins. In a paper published this July, researchers demonstrated the delivery of an extremely potent pan-RAS-cleaving enzyme, opening the door for the first targeted pan-RAS inhibitor for cancer therapy. In this episode we speak with two of the researchers from this project, a cancer biologist and a protein engineer, to learn what sparked their collaboration and what their system means for the future of cancer biologics.

  continue reading

65 episodes

Artwork
iconShare
 
Manage episode 299414652 series 2967424
Content provided by Cambridge Healthtech Institute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Cambridge Healthtech Institute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

There are some proteins that still evade scientists in the race for better therapeutics. Some of the most elusive drug targets in cancer research are RAS oncoproteins. In a paper published this July, researchers demonstrated the delivery of an extremely potent pan-RAS-cleaving enzyme, opening the door for the first targeted pan-RAS inhibitor for cancer therapy. In this episode we speak with two of the researchers from this project, a cancer biologist and a protein engineer, to learn what sparked their collaboration and what their system means for the future of cancer biologics.

  continue reading

65 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide